IP Verse

Means And Methods For Identifying A Patient Having A Braf-Positive Cancer As A Non-Responder To A Braf Inhibitor And As A Responder To An Mapk/Erk Inhibitor - EP3169797

The patent EP3169797 was granted to Universitt Zrich Prorektorat MNW on Feb 19, 2025. The application was originally filed on Jul 13, 2015 under application number EP15734713A. The patent is currently recorded with a legal status of "Patent Maintained As Amended".

EP3169797

UNIVERSITT ZRICH PROREKTORAT MNW
Application Number
EP15734713A
Filing Date
Jul 13, 2015
Status
Patent Maintained As Amended
Jan 17, 2025
Grant Date
Feb 19, 2025
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

STRAWMANMay 20, 2020ZWICKERADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2014018372
INTERNATIONAL-SEARCH-REPORTUS2014018405
INTERNATIONAL-SEARCH-REPORTWO2012058532
INTERNATIONAL-SEARCH-REPORTWO2012068468
INTERNATIONAL-SEARCH-REPORTWO2012068562
INTERNATIONAL-SEARCH-REPORTWO2014052613
OPPOSITIONWO2012061683
OPPOSITIONWO2012068468
OPPOSITIONWO2012068562
OPPOSITIONWO2014052613

Non-Patent Literature (NPL) Citations (19) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Amelie Clementine Seghers, Et Al, "Successful rechallenge in two patients with BRAF- 2012 V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor", Melanoma, (20120101), vol. 22, no. 6, pages 466 - 472, XP055741146-
OPPOSITION- Anonymous, "A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma", ClinicalTrials.gov archive, (20130130), pages 1 - 10, ClinicalTrials.gov archive, URL: https://clinicaltrials.gov/ct2/history/NCT01781572?V_1=View#StudyPageTop-accessed, (20190205), XP055551746-
OPPOSITION- Anonymous, "A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma - Full Text View - ClinicalTrials.gov. NCT01320085", Clinicaltrials.gov NCT01320085, (20140106), pages 1 - 4, Clinicaltrials.gov NCT01320085, URL: https://clinicaltrials.gov/ct2/show/NCT01320085, (20201019), XP055741171-
OPPOSITION- Anonymous, "Dabrafenib Alone and in Combination With Trametinib Before Surgery in Treating Patients With Locally or Regionally Advanced Melanoma That Can Be Removed By Surgery. NCT01701037", ClinicalTrials.gov NCT01701037, (20130101), pages 1 - 9, ClinicalTrials.gov NCT01701037, URL: https://clinicaltrials.gov/ct2/show/NCT01701037, (20201019), XP055741217-
OPPOSITION- Anonymous, "LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma (LOGIC-2) NCT02159066", ClinicalTrials.gov NCT02159066, (20140609), pages 1 - 5, ClinicalTrials.gov NCT02159066, URL: https://clinicaltrials.gov/ct2/show/NCT02159066, (20201019), XP055741173-
OPPOSITION- Anonymous, "Two new GSK oral oncology treatments, BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets, approved by FDA as single-agent therapies | GSK", GSK press release, (20130529), pages 1 - 18, GSK press release, URL: https://www.gsk.com/en-gb/media/press-releases/two-new-gsk-oral-oncology-treatments-braf-inhibitor-tafinlar-dabrafenib-capsules-and-the-first-mek-inhibitor-mekinist-trametinib-tablets-approved-by-fda-as-single-agent-therapies/, (20201019), XP055741226-
OPPOSITION- ASCIERTO et al., "Efficacy and safety of oral MEK162 in patients with 2012 locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations", Journal of Clinical Oncology, (20120000), vol. 30, no. 15, pages 8511 - 8511, XP055551785-
OPPOSITION- Deborah J Wong, Et Al, "Abstract 917: High antitumor activity of the ERK inhibitor SCH722984 against BRAF-mutant, NRAS-mutant and wild-type melanoma cell lines.", Proceedings: AACR 104th Annual Meeting 2013, (20130401), pages 1 - 4, XP055741211-
OPPOSITION- F Anonymous, "Media Release FDA approves Zelboraf (vemurafenib) and companion diagnostic for BRAF mutation-positive metastatic melanoma, a deadly form of skin cancer First and Only Personalized Medicine Shown to Help People With BRAF V600E Mutation-Positive Metastatic Melanoma, Found in Half of Melanoma Patients, Live Longer", Hoffmann-La Roche LTD media release, (20110817), pages 1 - 5, Hoffmann-La Roche LTD media release, URL: https://www.roche.com/dam/jcr:0a8fb4b8-9326-4110-ab50-045fe43120c3/en/med-cor-2011-08-17-e.pdf, (20201019), XP055741227-
OPPOSITION- Ramin Nazarian et al, "Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation", Nature, Macmillan Journals Ltd, London, London, (20101216), vol. 468, no. 7326, doi:10.1038/NATURE09626, ISSN 0028-0836, pages 973 - 979, XP002633500
OPPOSITION- FLAHERTY KEITH T, ET AL, "Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations", New England Journal of Medicine, Massachusetts Medical Society, US, US, (20121101), vol. 367, no. 18, doi:10.1056/NEJMoa1210093, ISSN 0028-4793, pages 1694 - 1703, XP002725869
OPPOSITION- KAPLAN et al., "SHOC2 and CRAF Mediate ERK1/2 Reactivation in 2012 Mutant NRAS-mediated Resistance to RAF Inhibitor", Journal Of Biological Chemistry, vol. 287, no. 50, doi:10.1074/jbc.M112.390906, pages 41797 - 41807, XP055156287
OPPOSITION- C. A. Pratilas, Et Al, "Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer", CANCER RESEARCH, American Association for Cancer Research., US, US, (20081115), vol. 68, no. 22, doi:10.1158/0008-5472.CAN-08-2223, ISSN 0008-5472, pages 9375 - 9383, XP055741223
OPPOSITION- SWANTO N, "Intratumor Heterogeneity: Evolution through Space and 2012 Time", Cancer Res, (20120000), vol. 72, doi:10.1158/0008-5472.CAN-12-2217, pages 4875 - 4882, XP055582395
OPPOSITION- ROMANO et al., "Identification of Multiple Mechanisms of Resistance to 2013 Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression", Clin Cancer Res, (20130000), vol. 19, doi:10.1158/1078-0432.CCR-13-0661, pages 5749 - 5757, XP055156251
OPPOSITION- GREGER et al., "Combinations of BRAF, MEK, and PI3K/mTOR 2012 Inhibitors Overcome Acquired Resistance to the BRAF Inhibitor GSK2118436 Dabrafenib, Mediated by NRAS or MEK Mutations", Mol Cancer Ther, (20120000), vol. 11, doi:10.1158/1535-7163.MCT-11-0989, pages 909 - 920, XP055057160
OPPOSITION- Deborah JL Wong et al, "Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma", MOLECULAR CANCER, BIOMED CENTRAL, LONDON, GB, GB, (20140820), vol. 13, no. 1, doi:10.1186/1476-4598-13-194, ISSN 1476-4598, page 194, XP021195962
OPPOSITION- THUMAR et al., "MEK targeting in N-RAS mutated metastatic melanoma", Molecular Cancer, vol. 13, doi:10.1186/1476-4598-13-45, (20140304), page 45, XP021178565
OPPOSITION- Marieke I. G. Raaijmakers, Et Al, "Co-existence of BRAF and NRAS driver mutations in the same melanoma cells results in heterogeneity of targeted therapy resistance", Oncotarget, (20161122), vol. 7, no. 47, doi:10.18632/oncotarget.12848, pages 77163 - 77174, XP055741139

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents